- Home
- SRBK vs TCRX Comparison
SRBK vs TCRX Comparison
Compare SRBK & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRBK
- TCRX
- Stock Information
- Founded
- SRBK 1887
- TCRX 2018
- Country
- SRBK United States
- TCRX United States
- Employees
- SRBK N/A
- TCRX N/A
- Industry
- SRBK
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SRBK
- TCRX Health Care
- Exchange
- SRBK Nasdaq
- TCRX Nasdaq
- Market Cap
- SRBK 117.4M
- TCRX 140.7M
- IPO Year
- SRBK N/A
- TCRX 2021
- Fundamental
- Price
- SRBK $14.72
- TCRX $1.94
- Analyst Decision
- SRBK
- TCRX Strong Buy
- Analyst Count
- SRBK 0
- TCRX 5
- Target Price
- SRBK N/A
- TCRX $9.40
- AVG Volume (30 Days)
- SRBK 26.2K
- TCRX 658.7K
- Earning Date
- SRBK 10-30-2025
- TCRX 11-07-2025
- Dividend Yield
- SRBK 1.36%
- TCRX N/A
- EPS Growth
- SRBK 374.69
- TCRX N/A
- EPS
- SRBK 0.54
- TCRX N/A
- Revenue
- SRBK $31,130,000.00
- TCRX $6,961,000.00
- Revenue This Year
- SRBK N/A
- TCRX $255.18
- Revenue Next Year
- SRBK N/A
- TCRX N/A
- P/E Ratio
- SRBK $27.17
- TCRX N/A
- Revenue Growth
- SRBK 0.85
- TCRX N/A
- 52 Week Low
- SRBK $10.55
- TCRX $1.02
- 52 Week High
- SRBK $15.46
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- SRBK 48.92
- TCRX 43.40
- Support Level
- SRBK $14.60
- TCRX $1.74
- Resistance Level
- SRBK $14.94
- TCRX $2.43
- Average True Range (ATR)
- SRBK 0.23
- TCRX 0.19
- MACD
- SRBK 0.01
- TCRX -0.06
- Stochastic Oscillator
- SRBK 58.02
- TCRX 24.10
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.